What is Aspira Womens Health Inc's earnings per share (EPS)?

Aspira Womens Health Inc (AWHL) reported diluted earnings per share of $-0.37 for fiscal year 2025. This represents a 60.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aspira Womens Health Inc Financials

AWHL

Source SEC Filings (10-K/10-Q) Updated Apr 1, 2026 Currency USD FYE April

This page shows Aspira Womens Health Inc (AWHL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 13/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Aspira Womens Health Inc has an operating margin of -85.9%, meaning the company retains $-86 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -177.3% the prior year.

Growth

Aspira Womens Health Inc's revenue grew a modest 0.4% year-over-year to $9.2M. This slow but positive growth earns a score of 34/100.

Liquidity

Aspira Womens Health Inc's current ratio of 1.17 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 19/100, which could limit financial flexibility.

Cash Flow

While Aspira Womens Health Inc generated -$7.0M in operating cash flow, capex of $16K consumed most of it, leaving -$7.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

6/9

Aspira Womens Health Inc passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.55x

For every $1 of reported earnings, Aspira Womens Health Inc generates $0.55 in operating cash flow (-$7.0M OCF vs -$12.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-239.8x

Aspira Womens Health Inc earns $-239.8 in operating income for every $1 of interest expense (-$7.9M vs $33K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.2M

YoY+0.4%

5Y CAGR+14.7%

10Y CAGR+15.5%

Aspira Womens Health Inc generated $9.2M in revenue in fiscal year 2025. This represents an increase of 0.4% from the prior year.

EBITDA

-$7.8M

YoY+51.8%

Aspira Womens Health Inc's EBITDA was -$7.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.8% from the prior year.

Net Income

-$12.8M

YoY+2.4%

Aspira Womens Health Inc reported -$12.8M in net income in fiscal year 2025. This represents an increase of 2.4% from the prior year.

EPS (Diluted)

$-0.37

YoY+60.2%

Aspira Womens Health Inc earned $-0.37 per diluted share (EPS) in fiscal year 2025. This represents an increase of 60.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$7.0M

YoY+42.0%

Aspira Womens Health Inc generated -$7.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 42.0% from the prior year.

Cash & Debt

$1.8M

YoY-0.8%

5Y CAGR-36.2%

10Y CAGR-21.0%

Aspira Womens Health Inc held $1.8M in cash against $1.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

44M

YoY+161.0%

Aspira Womens Health Inc had 44M shares outstanding in fiscal year 2025. This represents an increase of 161.0% from the prior year.

Margins & Returns

Gross Margin

64.2%

YoY+4.5pp

5Y CAGR+37.6pp

10Y CAGR+70.2pp

Aspira Womens Health Inc's gross margin was 64.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 4.5 percentage points from the prior year.

Operating Margin

-85.9%

YoY+91.4pp

5Y CAGR+300.8pp

10Y CAGR+798.3pp

Aspira Womens Health Inc's operating margin was -85.9% in fiscal year 2025, reflecting core business profitability. This is up 91.4 percentage points from the prior year.

Net Margin

-138.7%

YoY+3.9pp

5Y CAGR+246.3pp

10Y CAGR+739.4pp

Aspira Womens Health Inc's net profit margin was -138.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.9 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.9M

YoY-11.9%

5Y CAGR+6.5%

10Y CAGR-2.6%

Aspira Womens Health Inc invested $2.9M in research and development in fiscal year 2025. This represents a decrease of 11.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

YoY-56.8%

5Y CAGR-49.6%

10Y CAGR-24.9%

Aspira Womens Health Inc invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 56.8% from the prior year.

AWHL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$9.2M+0.4%	$9.2M+0.3%	$9.2M+11.9%	$8.2M+20.1%	$6.8M+46.5%	$4.7M
Cost of Revenue	$3.3M-10.9%	$3.7M-4.9%	$3.9M+0.8%	$3.9M+3.0%	$3.8M+9.8%	$3.4M
Gross Profit	$5.9M+8.0%	$5.5M+4.1%	$5.3M+21.7%	$4.3M+41.2%	$3.1M+147.7%	$1.2M
R&D Expenses	$2.9M-11.9%	$3.3M-19.1%	$4.0M-31.8%	$5.9M+11.3%	$5.3M+152.6%	$2.1M
SG&A Expenses	$8.0M-23.0%	$10.3M-15.7%	$12.3M-16.1%	$14.6M+10.3%	$13.3M+60.3%	$8.3M
Operating Income	-$7.9M+51.4%	-$16.3M+13.7%	-$18.9M+39.5%	-$31.1M+4.5%	-$32.6M-81.3%	-$18.0M
Interest Expense	$33K+200.0%	-$33K-168.8%	$48K+182.4%	$17K+135.4%	-$48K-580.0%	$10K
Income Tax	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$12.8M+2.4%	-$13.1M+21.5%	-$16.7M+44.2%	-$29.9M+5.6%	-$31.7M-76.8%	-$17.9M
EPS (Diluted)	$-0.37+60.2%	$-0.93+48.6%	$-1.81+53.0%	$-3.85+9.8%	$-4.27	$-0.18

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$2.3M-4.1%	$2.4M+5.5%	$2.3M-3.0%	$2.3M+4.1%	$2.3M-6.9%	$2.4M+12.5%	$2.2M+1.1%	$2.1M
Cost of Revenue	$922K+6.0%	$870K+21.0%	$719K-16.4%	$860K-4.7%	$902K-10.0%	$1.0M+6.7%	$939K+3.1%	$911K
Gross Profit	$1.4M-9.8%	$1.5M-1.7%	$1.6M+4.8%	$1.5M+9.9%	$1.4M-4.6%	$1.4M+17.1%	$1.2M-0.4%	$1.2M
R&D Expenses	$739K+5.0%	$704K-27.6%	$973K+94.6%	$500K-44.9%	$908K-4.6%	$952K+5.1%	$906K-15.9%	$1.1M
SG&A Expenses	$1.5M-21.5%	$2.0M-28.5%	$2.7M+12.2%	$2.4M+19.3%	$2.0M-24.8%	$2.7M-12.9%	$3.1M+23.5%	$2.5M
Operating Income	-$1.6M+12.8%	-$1.8M+44.1%	-$3.2M+5.6%	-$3.4M+8.4%	-$3.7M+14.8%	-$4.4M+6.7%	-$4.7M-13.9%	-$4.1M
Interest Expense	-$13K0.0%	-$13K+7.1%	-$14K-7.7%	-$13K-160.0%	-$5K+50.0%	-$10K-100.0%	-$5K-350.0%	$2K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.9M-83.5%	-$2.7M-43.9%	-$1.9M-33.5%	-$1.4M+60.9%	-$3.5M-0.5%	-$3.5M+23.7%	-$4.6M-49.9%	-$3.1M
EPS (Diluted)	$-0.13-85.7%	$-0.07+22.2%	$-0.09	N/A	$-0.23+17.9%	$-0.28+28.2%	$-0.39	N/A

AWHL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.5M-0.6%	$5.5M-12.3%	$6.3M-64.0%	$17.4M-57.7%	$41.1M+109.5%	$19.6M
Current Assets	$4.1M-2.9%	$4.2M-20.8%	$5.3M-67.6%	$16.3M-59.2%	$40.0M+115.0%	$18.6M
Cash & Equivalents	$1.8M-0.8%	$1.8M-31.9%	$2.6M-80.5%	$13.3M-64.2%	$37.2M+123.6%	$16.6M
Inventory	$256K-21.5%	$326K+43.6%	$227K-28.2%	$316K+81.6%	$174K+480.0%	$30K
Accounts Receivable	$1.2M+21.9%	$990K-32.1%	$1.5M+17.2%	$1.2M+21.2%	$1.0M+18.7%	$865K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.4M+53.8%	$8.1M-6.6%	$8.6M-17.0%	$10.4M-4.7%	$10.9M+10.3%	$9.9M
Current Liabilities	$3.5M-36.6%	$5.5M+6.8%	$5.1M-7.4%	$5.5M-29.5%	$7.8M+30.7%	$6.0M
Long-Term Debt	$1.0M-18.5%	$1.3M-10.6%	$1.4M-38.2%	$2.3M-14.8%	$2.7M-21.8%	$3.5M
Total Equity	-$6.9M-170.5%	-$2.6M-8.4%	-$2.4M-133.9%	$7.0M-76.9%	$30.2M+210.4%	$9.7M
Retained Earnings	-$544.2M-2.4%	-$531.4M-2.5%	-$518.3M-3.3%	-$501.6M-6.3%	-$471.7M-7.2%	-$440.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$7.3M+47.9%	$4.9M-26.5%	$6.7M+22.3%	$5.5M+15.4%	$4.8M-13.3%	$5.5M-23.4%	$7.2M+14.4%	$6.3M
Current Assets	$5.8M+58.0%	$3.7M-31.6%	$5.4M+28.9%	$4.2M+1.7%	$4.1M+26.5%	$3.3M-46.9%	$6.1M+15.9%	$5.3M
Cash & Equivalents	$3.8M+146.5%	$1.5M-53.4%	$3.3M+87.2%	$1.8M-17.1%	$2.1M+121.7%	$962K-71.8%	$3.4M+31.4%	$2.6M
Inventory	$282K+3.3%	$273K+5.0%	$260K-20.2%	$326K+12.4%	$290K+28.3%	$226K-4.2%	$236K+4.0%	$227K
Accounts Receivable	$1.3M+3.1%	$1.3M+16.2%	$1.1M+11.1%	$990K-21.1%	$1.3M-13.2%	$1.4M-5.6%	$1.5M+4.9%	$1.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.6M+52.8%	$7.6M+12.4%	$6.8M-15.9%	$8.1M+10.6%	$7.3M-20.9%	$9.2M+7.9%	$8.5M-1.2%	$8.6M
Current Liabilities	$4.2M+2.5%	$4.1M+8.1%	$3.8M-30.7%	$5.5M0.0%	$5.5M+0.1%	$5.5M+3.1%	$5.3M+3.4%	$5.1M
Long-Term Debt	$1.1M-5.2%	$1.2M-4.8%	$1.2M-4.6%	$1.3M-4.2%	$1.3M+5.5%	$1.3M-6.2%	$1.3M-5.8%	$1.4M
Total Equity	-$4.3M-61.8%	-$2.7M-4375.0%	-$60K+97.7%	-$2.6M-1.7%	-$2.5M+32.1%	-$3.7M-172.1%	-$1.4M+42.4%	-$2.4M
Retained Earnings	-$540.8M-0.9%	-$535.9M-0.5%	-$533.3M-0.3%	-$531.4M-0.3%	-$530.0M-0.7%	-$526.5M-0.7%	-$522.9M-0.9%	-$518.3M

AWHL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.0M+42.0%	-$12.1M+23.8%	-$15.9M+48.8%	-$31.1M-13.4%	-$27.4M-85.9%	-$14.7M
Capital Expenditures	$16K-56.8%	$37K+54.2%	$24K-89.7%	$232K+26.1%	$184K-62.4%	$490K
Free Cash Flow	-$7.0M+42.0%	-$12.2M+23.7%	-$15.9M+49.1%	-$31.3M-13.5%	-$27.6M-81.2%	-$15.2M
Investing Cash Flow	-$401K-983.8%	-$37K-54.2%	-$24K+89.7%	-$232K-26.1%	-$184K+62.4%	-$490K
Financing Cash Flow	$7.4M-33.0%	$11.1M+112.1%	$5.2M-29.8%	$7.4M-84.6%	$48.4M+140.1%	$20.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$212K+87.8%	-$1.7M+44.1%	-$3.1M-203.8%	-$1.0M+65.0%	-$2.9M+21.9%	-$3.7M+15.6%	-$4.4M-28.4%	-$3.5M
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$2K-86.7%	$15K-25.0%	$20K+66.7%	$12K
Free Cash Flow	N/A	N/A	N/A	-$1.0M+65.1%	-$2.9M+22.2%	-$3.8M+15.6%	-$4.5M-28.6%	-$3.5M
Investing Cash Flow	N/A	N/A	N/A	$0+100.0%	-$2K+86.7%	-$15K+25.0%	-$20K-66.7%	-$12K
Financing Cash Flow	$2.9M+8793.9%	-$33K-100.7%	$4.6M+607.0%	$657K-83.9%	$4.1M+291.7%	$1.0M-80.2%	$5.3M+448.3%	$961K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AWHL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	64.2%+4.5pp	59.7%+2.2pp	57.5%+4.7pp	52.8%+7.9pp	45.0%+18.4pp	26.6%
Operating Margin	-85.9%+91.4pp	-177.3%+28.7pp	-205.9%+174.5pp	-380.5%+98.0pp	-478.5%-91.9pp	-386.6%
Net Margin	-138.7%+3.9pp	-142.6%+39.7pp	-182.3%+182.8pp	-365.2%+99.6pp	-464.8%-79.8pp	-385.0%
Return on Equity	N/A	N/A	N/A	-428.2%-323.3pp	-104.9%+79.3pp	-184.2%
Return on Assets	-234.2%+4.2pp	-238.5%+28.1pp	-266.5%-94.5pp	-172.0%-94.9pp	-77.1%+14.2pp	-91.3%
Current Ratio	1.17+0.4	0.77-0.3	1.03-1.9	2.95-2.2	5.10+2.0	3.10
Debt-to-Equity	-0.15+0.3	-0.50+0.1	-0.60-0.9	0.33+0.2	0.09-0.3	0.36
FCF Margin	-76.4%+55.9pp	-132.3%+41.6pp	-173.9%+208.6pp	-382.4%+22.4pp	-404.9%-77.5pp	-327.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	60.0%-3.8pp	63.8%-4.6pp	68.5%+5.1pp	63.4%+3.3pp	60.0%+1.4pp	58.7%+2.3pp	56.4%-0.8pp	57.2%
Operating Margin	-68.5%+6.8pp	-75.3%+66.9pp	-142.2%+3.9pp	-146.1%+19.8pp	-165.9%+15.4pp	-181.3%+37.5pp	-218.8%-24.6pp	-194.1%
Net Margin	-212.2%-101.3pp	-110.9%-29.6pp	-81.3%-22.2pp	-59.1%+98.1pp	-157.2%-11.5pp	-145.7%+69.3pp	-215.0%-70.0pp	-145.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-67.0%-13.0pp	-54.0%-26.4pp	-27.6%-2.3pp	-25.3%+49.2pp	-74.5%-10.2pp	-64.3%+0.3pp	-64.6%-15.3pp	-49.3%
Current Ratio	1.39+0.5	0.90-0.5	1.42+0.7	0.77+0.0	0.75+0.2	0.60-0.6	1.16+0.1	1.03
Debt-to-Equity	-0.25+0.2	-0.43+19.9	-20.32-19.8	-0.50+0.0	-0.53-0.2	-0.34+0.6	-0.99-0.4	-0.60
FCF Margin	N/A	N/A	N/A	-43.5%+86.0pp	-129.5%+25.6pp	-155.0%+51.7pp	-206.7%-44.2pp	-162.5%

Note: Shareholder equity is negative (-$6.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

CELLBXHEALTH PLC ANPCY

$17.5M

Izotropic Canada IZOZF

$11.3M

Immunovia Ab IMMVF

$16.6M

Biomark Diagnostics Inc BMKDF

$44.6M

Angle Plc Surrey ANPCF

$20.1M

Frequently Asked Questions

What is Aspira Womens Health Inc's annual revenue?

Aspira Womens Health Inc (AWHL) reported $9.2M in total revenue for fiscal year 2025. This represents a 0.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Aspira Womens Health Inc's revenue growing?

Aspira Womens Health Inc (AWHL) revenue grew by 0.4% year-over-year, from $9.2M to $9.2M in fiscal year 2025.

Is Aspira Womens Health Inc profitable?

No, Aspira Womens Health Inc (AWHL) reported a net income of -$12.8M in fiscal year 2025, with a net profit margin of -138.7%.

What is Aspira Womens Health Inc's EBITDA?

Aspira Womens Health Inc (AWHL) had EBITDA of -$7.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Aspira Womens Health Inc have?

As of fiscal year 2025, Aspira Womens Health Inc (AWHL) had $1.8M in cash and equivalents against $1.0M in long-term debt.

What is Aspira Womens Health Inc's gross margin?

Aspira Womens Health Inc (AWHL) had a gross margin of 64.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Aspira Womens Health Inc's operating margin?

Aspira Womens Health Inc (AWHL) had an operating margin of -85.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Aspira Womens Health Inc's net profit margin?

Aspira Womens Health Inc (AWHL) had a net profit margin of -138.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Aspira Womens Health Inc's free cash flow?

Aspira Womens Health Inc (AWHL) generated -$7.0M in free cash flow during fiscal year 2025. This represents a 42.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aspira Womens Health Inc's operating cash flow?

Aspira Womens Health Inc (AWHL) generated -$7.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aspira Womens Health Inc's total assets?

Aspira Womens Health Inc (AWHL) had $5.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Aspira Womens Health Inc's capital expenditures?

Aspira Womens Health Inc (AWHL) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aspira Womens Health Inc spend on research and development?

Aspira Womens Health Inc (AWHL) invested $2.9M in research and development during fiscal year 2025.

How many shares does Aspira Womens Health Inc have outstanding?

Aspira Womens Health Inc (AWHL) had 44M shares outstanding as of fiscal year 2025.

What is Aspira Womens Health Inc's current ratio?

Aspira Womens Health Inc (AWHL) had a current ratio of 1.17 as of fiscal year 2025, which is considered adequate.

What is Aspira Womens Health Inc's debt-to-equity ratio?

Aspira Womens Health Inc (AWHL) had a debt-to-equity ratio of -0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aspira Womens Health Inc's return on assets (ROA)?

Aspira Womens Health Inc (AWHL) had a return on assets of -234.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aspira Womens Health Inc's cash runway?

Based on fiscal year 2025 data, Aspira Womens Health Inc (AWHL) had $1.8M in cash against an annual operating cash burn of $7.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Aspira Womens Health Inc's debt-to-equity ratio negative or unusual?

Aspira Womens Health Inc (AWHL) has negative shareholder equity of -$6.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Aspira Womens Health Inc's Piotroski F-Score?

Aspira Womens Health Inc (AWHL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aspira Womens Health Inc's earnings high quality?

Aspira Womens Health Inc (AWHL) has an earnings quality ratio of 0.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Aspira Womens Health Inc cover its interest payments?

Aspira Womens Health Inc (AWHL) has an interest coverage ratio of -239.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Aspira Womens Health Inc?

Aspira Womens Health Inc (AWHL) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.